SPY328.73+5.23 1.62%
DIA271.70+3.60 1.34%
IXIC10,913.56+241.30 2.26%

Ovid Therapeutics shares are trading higher after the company, and Takeda Pharmaceutical, announced the Phase 2 ELEKTRA study of Soticlestat met its primary endpoint, reducing seizure frequency in children with Dravet Syndrome or Lennox-Gastaut Syndrome.

Benzinga · 08/25/2020 14:15